The biomarker and clinical data are strongly positive and de-risk the DT-216P2 program for Friedreich ataxia. The company's plan to pursue a registrational path suggests confidence in the data package. Traders should watch for the Q4 2026 update on registrational plans and any partnership or financing announcements that may follow this data readout.
Price Chart
Executive Summary
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich ataxia. At the 1 mpk dose, patients showed a 65% increase in whole blood FXN mRNA (p<0.001), 22-27% increases in FXN protein levels (p<0.001), and a 42% increase in muscle FXN mRNA (p=0.015). Clinically, patients improved by 6.4 points on the modified Friedreich's Ataxia Rating Scale and 2.7 points on the Upright Stability Score, with fatigue improvements exceeding the minimal important change threshold. The drug was well-tolerated with no serious adverse events. The company plans to pursue a registrational path and provide an update in Q4 2026.
Key Facts
- 16 patients completed 4 weeks of DT-216P2 treatment across 4 dose cohorts (0.1, 0.3, 0.6, 1 mpk)
- At 1 mpk: whole blood FXN mRNA increased 65% from baseline (p<0.001)
- At 1 mpk: whole blood FXN-M and FXN-E protein increased 22-27% from baseline (p<0.001)
- At 1 mpk: muscle FXN mRNA increased 42% from baseline (p=0.015)
- At 1 mpk: mean improvement of 6.4 points on modified Friedreich's Ataxia Rating Scale
- At 1 mpk: mean improvement of 2.7 points on Upright Stability Score
- Patient-reported fatigue (PROMIS) improved >5 points, exceeding the 3-point minimal important change threshold
- No serious adverse events or treatment discontinuations; mild-to-moderate transient ALT elevations in 3 patients
- Company intends to pursue registrational path with update in Q4 2026
Financial Impact
No financial figures provided in the filing; market impact driven by clinical data quality and registrational path announcement
Risk Factors
- Data is from a small Phase 1/2 trial (n=16) and may not replicate in larger registrational studies
- Transient ALT elevations, while mild, could become a safety signal in longer-term or larger trials
- Registrational path and timeline are uncertain; company needs to provide specific plans in Q4 2026
- Pre-revenue biotech with no approved products; will require additional capital to fund registrational trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-227875 |
| Document: 0001193125-26-227875-index-headers.html | 0001193125-26-227875 |
| Document: 0001193125-26-227875-index.html | 0001193125-26-227875 |
| Document: 0001193125-26-227875.txt | 0001193125-26-227875 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.40 (−18.50%) |
Aug 3, 2026 12w ago | Press Release | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.40 (−18.50%) |
May 18, 2026 23w ago | 8-K | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
May 18, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
May 17, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
Apr 28, 2026 25w ago | Press Release | $15.79 $11.10 | ▼ −29.70% | ▼ −35.16% | $10.40 (−34.14%) |
Apr 23, 2026 26w ago | DEFA14A | $12.53 $11.01 | ▼ −12.13% | ▼ −16.16% | $10.40 (−17.00%) |
Apr 1, 2026 29w ago | 3 | $11.23 $13.60 | ▲ +21.10% | ▲ +11.23% | $10.40 (−7.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers